Ellie J C Goldstein Selected Research

Ertapenem (Invanz)

4/2009	Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis.
4/2009	Activity of a novel carbapenem, doripenem, against anaerobic pathogens.
2/2008	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
9/2007	Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents.
6/2004	Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy.
6/2004	Treatment of complicated community-acquired infections with ertapenem, the first Group 1 carbapenem. Introduction.
11/2002	Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection.
9/2002	General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.
4/2002	Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ellie J C Goldstein Research Topics

Disease

38	Infections 06/2023 - 03/2002
15	Clostridium Infections 11/2021 - 02/2011
9	Intraabdominal Infections 08/2018 - 09/2002
9	Wounds and Injuries (Trauma) 01/2018 - 04/2003
8	Bites and Stings (Sting) 01/2018 - 03/2002
7	Diabetic Foot 02/2017 - 08/2006
6	Diarrhea 04/2021 - 12/2009
6	Coinfection 04/2021 - 06/2004
6	Soft Tissue Infections 02/2017 - 09/2002
5	Sinusitis 01/2007 - 02/2002
3	Cross Infection (Nosocomial Infection) 04/2017 - 12/2009
2	Bacteremia 03/2023 - 02/2017
2	Peritonitis 03/2022 - 08/2006
2	Osteomyelitis 05/2015 - 08/2014
2	Obesity 05/2015 - 09/2014
2	Pelvic Infection 05/2011 - 11/2002
2	Respiratory Tract Infections (Respiratory Tract Infection) 01/2007 - 04/2003
2	Community-Acquired Infections 06/2004 - 06/2004
2	Human Bites (Bite, Human) 09/2002 - 03/2002
1	Ventilator-Associated Pneumonia 04/2021
1	COVID-19 04/2021
1	Human Influenza (Influenza) 04/2021
1	Kidney Diseases (Kidney Disease) 03/2021
1	Malnutrition (Nutritional Deficiencies) 11/2019
1	Communicable Diseases (Infectious Diseases) 01/2019
1	Acinetobacter Infections 06/2017
1	Respiratory Insufficiency (Respiratory Failure) 04/2017
1	Pyelonephritis 01/2016
1	Urinary Tract Infections (Urinary Tract Infection) 01/2016
1	Rabies (Hydrophobia) 10/2015
1	Campylobacter Infections (Campylobacter Infection) 10/2015
1	Histoplasmosis 10/2015
1	Scabies (Sarcoptic Mange) 10/2015
1	Ehrlichiosis 10/2015
1	Fibrosis (Cirrhosis) 07/2014
1	Hypoalbuminemia 12/2013
1	Renal Insufficiency (Renal Failure) 12/2013
1	Reinfection 08/2012
1	Colitis 02/2011

Drug/Important Bio-Agent (IBA)

18	Anti-Bacterial Agents (Antibiotics)IBA 10/2021 - 03/2002
9	Ertapenem (Invanz)FDA Link 04/2009 - 04/2002
8	FluoroquinolonesIBA 04/2017 - 09/2002
7	Carbapenems (Carbapenem Antibiotics)IBA 03/2021 - 09/2002
6	Anti-Infective Agents (Microbicides)IBA 01/2017 - 02/2002
4	Vancomycin FDA LinkGeneric 08/2018 - 11/2011
4	Levofloxacin (Levaquin)FDA Link 01/2016 - 04/2003
4	AgarIBA 05/2009 - 01/2005
4	Methicillin (Metin)FDA Link 04/2008 - 08/2006
4	Tazobactam Drug Combination Piperacillin (Zosyn)FDA LinkGeneric 09/2007 - 09/2002
3	Ceftaroline FDA Link 05/2015 - 12/2012
3	16S Ribosomal RNAIBA 07/2014 - 08/2006
3	FidaxomicinIBA 12/2013 - 11/2011
3	Imipenem FDA Link 01/2012 - 02/2008
3	Doripenem FDA Link 01/2012 - 02/2008
3	Meropenem (Merrem)FDA LinkGeneric 01/2012 - 09/2002
3	Moxifloxacin (Avelox)FDA Link 12/2011 - 01/2006
3	Metronidazole (Metric)FDA LinkGeneric 07/2011 - 11/2002
3	AntralIBA 09/2003 - 02/2002
2	bezlotoxumabIBA 11/2021 - 01/2020
2	pexigananIBA 12/2017 - 01/2017
2	dalbavancinIBA 08/2014 - 08/2006
2	Linezolid (Zyvox)FDA Link 08/2014 - 03/2005
2	Rifampin (Rifampicin)FDA LinkGeneric 08/2014 - 07/2014
2	garenoxacinIBA 05/2011 - 03/2002
2	telithromycin (Ketek)FDA Link 01/2007 - 06/2003
2	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 06/2004 - 11/2002
2	Amoxicillin-Potassium Clavulanate Combination (Co-amoxiclav)FDA Link 06/2004 - 11/2002
1	TriazolesIBA 03/2022
1	Monoclonal AntibodiesIBA 11/2021
1	IronIBA 03/2021
1	yersiniabactinIBA 03/2021
1	O Antigens (O Antigen)IBA 03/2021
1	actoxumabIBA 01/2020
1	GoldIBA 01/2019
1	Investigational DrugsIBA 01/2019
1	eravacyclineIBA 08/2018
1	omadacyclineIBA 01/2018
1	Cephalosporins (Cephalosporin Antibiotics)IBA 04/2017
1	tedizolidIBA 02/2017
1	ridinilazoleIBA 08/2016
1	CB-183,315IBA 04/2016
1	LipopeptidesIBA 04/2016
1	tazobactam drug combination ceftolozaneIBA 01/2016
1	Proton Pump InhibitorsIBA 09/2014
1	Daptomycin FDA Link 08/2014
1	Doxycycline (Periostat)FDA LinkGeneric 08/2014
1	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 08/2014
1	avibactamIBA 07/2013
1	ProdrugsIBA 12/2012

Therapy/Procedure

16	Therapeutics 10/2021 - 09/2002
4	Punctures 10/2015 - 02/2002
3	Length of Stay 03/2021 - 12/2009
2	Central Venous Catheters 03/2023 - 04/2017
1	Secondary Prevention 06/2023
1	Investigational Therapies (Experimental Therapy) 01/2020
1	Tracheostomy 04/2017
1	Long-Term Care 05/2015
1	Shoulder Prosthesis 07/2014
1	Breast Implants (Breast Implant) 07/2014
1	Aftercare (After-Treatment) 08/2012